Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of CD19/CD22 CAR-T Cell Therapy as First-line Consolidation Treatment in Patients With Follicular Lymphoma

NCT07587840 is registered in ClinicalTrials.gov with Liping Dou as lead sponsor.

NCT NCT07587840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of CD19/CD22 CAR-T Cell Therapy as First-line Consolidation Treatment in Patients With Follicular Lymphoma
Lead sponsor
Liping Dou
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
January 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma